



## Cancer Project 2015-2016

### MEASURE-BY-MEASURE

**Measure #0219**

**Post Breast Conservation Surgery Irradiation**

\_\_\_\_\_

I approve this measure for NQF endorsement

\_\_\_\_\_

I do not approve this measure for NQF endorsement

\_\_\_\_\_

I abstain from voting on this measure

**Measure #0220:**

**Adjuvant Hormonal Therapy**

\_\_\_\_\_

I approve this measure for NQF endorsement

\_\_\_\_\_

I do not approve this measure for NQF endorsement

\_\_\_\_\_

I abstain from voting on this measure

**Measure #0223:**

**Adjuvant Chemotherapy s Recommended or Administered within 4 Months (120 days) of Diagnosis to Patients Under the Age of 80 with AJCC III (lymph node positive) Colon Cancer**

\_\_\_\_\_

I approve this measure for NQF endorsement

\_\_\_\_\_

I do not approve this measure for NQF endorsement

\_\_\_\_\_

I abstain from voting on this measure

**Measure #0225      At Least 12 Regional Lymph Nodes are Removed and Pathologically Examined for Resected Colon Cancer**

\_\_\_\_\_ I approve this measure for NQF endorsement  
\_\_\_\_\_ I do not approve this measure for NQF endorsement  
\_\_\_\_\_ I abstain from voting on this measure

**Measure #0377      Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow**

\_\_\_\_\_ I approve this measure for NQF endorsement  
\_\_\_\_\_ I do not approve this measure for NQF endorsement  
\_\_\_\_\_ I abstain from voting on this measure

**Measure #0378      Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy**

\_\_\_\_\_ I approve this measure for NQF endorsement  
\_\_\_\_\_ I do not approve this measure for NQF endorsement  
\_\_\_\_\_ I abstain from voting on this measure

**Measure #0389      Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients**

\_\_\_\_\_ I approve this measure for NQF endorsement  
\_\_\_\_\_ I do not approve this measure for NQF endorsement  
\_\_\_\_\_ I abstain from voting on this measure

**Measure #0390      Prostate Cancer: Adjuvant Hormonal Therapy for High or Very High Risk Prostate Cancer Patients**

\_\_\_\_\_ I approve this measure for NQF endorsement  
\_\_\_\_\_ I do not approve this measure for NQF endorsement  
\_\_\_\_\_ I abstain from voting on this measure

**Measure #0508**

**Diagnostic Imaging: Inappropriate Use of “Probably Benign”  
Assessment Category in Screening Mammograms**

- \_\_\_\_\_ I approve this measure for NQF endorsement
- \_\_\_\_\_ I do not approve this measure for NQF endorsement
- \_\_\_\_\_ I abstain from voting on this measure

**Measure #0509**

**Diagnostic Imaging: Reminder System for Screening Mammograms**

- \_\_\_\_\_ I approve this measure for NQF endorsement
- \_\_\_\_\_ I do not approve this measure for NQF endorsement
- \_\_\_\_\_ I abstain from voting on this measure

**Measure #0559**

**Combination chemotherapy is recommended or administered within 4  
months (120 days) of diagnosis for women under 70 with AJCC  
T1cN0M0, or Stage IB - III hormone receptor negative breast cancer**

- \_\_\_\_\_ I approve this measure for NQF endorsement
- \_\_\_\_\_ I do not approve this measure for NQF endorsement
- \_\_\_\_\_ I abstain from voting on this measure

**Measure #1857**

**HER 2 Negative or Undocumented Breast Cancer Patients Spared  
Treatment with HER2-Targeted Therapies – Recommended for  
Reserve Status**

- \_\_\_\_\_ I approve this measure for NQF endorsement
- \_\_\_\_\_ I do not approve this measure for NQF endorsement
- \_\_\_\_\_ I abstain from voting on this measure

**Measure #1878**

**HER2 Testing for Overexpression or Gene Amplification in Patients  
with Breast Cancer Recommended for Reserve Status**

- \_\_\_\_\_ I approve this measure for NQF endorsement
- \_\_\_\_\_ I do not approve this measure for NQF endorsement

**ELECTRONIC VOTING ONLY—VOTING CLOSES Thursday, Sept. 21, 2016, at 6:00PM ET.**

\_\_\_\_\_ I abstain from voting on this measure

**Measure #2930      Febrile Neutropenia Risk Assessment Prior to Chemotherapy**

\_\_\_\_\_ I approve this measure for NQF endorsement

\_\_\_\_\_ I do not approve this measure for NQF endorsement

\_\_\_\_\_ I abstain from voting on this measure

**Measure #2963      Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients - Legacy eMeasure**

\_\_\_\_\_ I approve this measure for NQF endorsement

\_\_\_\_\_ I do not approve this measure for NQF endorsement

\_\_\_\_\_ I abstain from voting on this measure